Previous Page
26
nanotimes
Companies Facts
Led by the father of digital commercial printing, Benny Landa, who started the digital printing revo- lution in 1993 with the launch of the iconic Indigo digital press, Landa is now set to ignite the second di- gital revolution in print. Landa Nanographic Printing Presses offer the versatility of digital with the qualities and speed of offset printing – at unmatched cost-per- page.
“It‘s good to be back,” says Benny Landa, Chair- man and CEO. “The Landa Nanographic Prin- ting™ process is the result of ten years of nano- technology research. It is a true breakthrough that enables our presses to achieve amazing results.”
lysis capabilities in a single platform, with precision cell modelling, Tissue IA 2.0 offers a superior solu- tion for IHC biomarker quantification. Tissue IA 2.0 joins the Total Digital Pathology portfolio from Leica, providing streamlined end-to-end excellence in cap- ture, management and analysis of digital pathology images.
http://www.leica-microsystems.com/products/digital-pa- thology/analyze/details/product/tissue-ia/
L iquidmetal® Technologies Inc. (OTCBB: LQMT) announced its financial results for the three
months ended and year ended December 31, 2011. The Company reported revenues of $0.25 million and $1 million for the fourth quarter ended and year ended December 31, 2011, respectively. Furthermo- re, the Company closed out the fourth quarter with an operating loss of $1.7 million and $6.5 million for the year end.
http://www.liquidmetal.com M L
eica Microsystems released Tissue IA 2.0, high performance image analysis for discovery re- search. Combining fluorescence and brightfield ana-
agForce AG (Frankfurt, XETRA: MF6), a me- dical technology company focusing on nano-
medicine in oncology announced the company‘s restructuring and revised corporate strategy for 2012. The company reduced its headcount from 52 em- ployees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. The implemented cost reductions will enable the company to work more effectively and concentrate on clinical development activities to support the market introduction of NanoTherm®
therapy.
12-03 :: March/April 2012